Research from Redeye, Redeye AB

Redeye

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye leaves a comment following OncoZenge’s announcement of an amended agreement with Molteni Farmaceutici, transferring full responsibility for the commercial-scale manufacturing of BupiZenge to the Italian partner.</li><li>We view this as a strategically positive development that reinforces OncoZenge's asset-light model and de-risks the commercialization pathway.</li></ul>

Redeye leaves a comment following OncoZenge’s announcement of an amended agreement with Molteni Farmaceutici, transferring full responsibility for the commercial-scale manufacturing of BupiZenge to the Italian partner.We view this as a strategically positive development that reinforces OncoZenge's asset-light model and de-risks the commercialization pathway.

OncoZenge: De-risked commercial supply through expanded Molteni partnership

<ul><li>Redeye leaves a short comment following OncoZenge’s announcement that UCLA has enrolled the first patient in its patient engagement study for BupiZenge.</li><li>We view this as an encouraging step in the company’s development strategy, providing valuable patient and clinician insights that could strengthen both the upcoming European CTA submission and future US regulatory interactions.</li></ul>

Redeye leaves a short comment following OncoZenge’s announcement that UCLA has enrolled the first patient in its patient engagement study for BupiZenge.We view this as an encouraging step in the company’s development strategy, providing valuable patient and clinician insights that could strengthen both the upcoming European CTA submission and future US regulatory interactions.

OncoZenge: UCLA engagement study enrolls first patient

<ul><li>Redeye leaves a comment following OncoZenge’s announcement of a collaboration with UCLA, marking an important first step toward a potential future US market entry for BupiZenge.</li><li>We view this initiative as a strategically sound move that broadens the scope of the program beyond Europe, while also providing valuable patient insights to support future regulatory and clinical planning in the US.</li></ul>

Redeye leaves a comment following OncoZenge’s announcement of a collaboration with UCLA, marking an important first step toward a potential future US market entry for BupiZenge.We view this initiative as a strategically sound move that broadens the scope of the program beyond Europe, while also providing valuable patient insights to support future regulatory and clinical planning in the US.

<ul><li>Redeye comments on OncoZenge’s announcement of appointing LINK Medical as CRO for its pivotal phase III trial with BupiZenge.</li><li>We view this as a natural and strategically sound step following the feasibility study conducted by LINK, ensuring both continuity and regional expertise as the company advances toward European market approval.</li></ul>

Redeye comments on OncoZenge’s announcement of appointing LINK Medical as CRO for its pivotal phase III trial with BupiZenge.We view this as a natural and strategically sound step following the feasibility study conducted by LINK, ensuring both continuity and regional expertise as the company advances toward European market approval.

OncoZenge: Appoints LINK Medical as CRO for the phase III study

Sweden

OncoZenge AB (publ), a pharmaceutical company, engages in the a development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oncozenge (ONCOZ SF)

OncoZenge: De-risked commercial supply through expanded Molteni partnership

Redeye leaves a comment following OncoZenge’s announcement of an amended agreement with Molteni Farmaceutici, transferring full responsibility for...

Redeye

OncoZenge: UCLA engagement study enrolls first patient

Redeye leaves a short comment following OncoZenge’s announcement that UCLA has enrolled the first patient in its patient engagement study for...

Redeye

OncoZenge: Partnership with UCLA

Redeye leaves a comment following OncoZenge’s announcement of a collaboration with UCLA, marking an important first step toward a potential future...

Redeye

OncoZenge: Appoints LINK Medical as CRO for the phase III study

Redeye comments on OncoZenge’s announcement of appointing LINK Medical as CRO for its pivotal phase III trial with BupiZenge. We view this as a...

Redeye

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)